Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer

Background: It is still controversial to employ osimertinib as the first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC) patients in practice. The aim of the current study was to explore the risk factors of acquired T790M mutation during EGFR-TKIs therapy, and to identify the potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, Wen, Yu, Jing, Huang, Zhao, Chen, Gang, Liu, Yu, Liao, Zhengkai, Zeng, Wei, Zhang, Junhong, Xie, Conghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052924/
https://www.ncbi.nlm.nih.gov/pubmed/32127933
http://dx.doi.org/10.7150/jca.37991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052924/
https://www.ncbi.nlm.nih.gov/pubmed/32127933
http://dx.doi.org/10.7150/jca.37991

Ejemplares similares